Breaking News Instant updates and real-time market news.

VTVT

vTv Therapeutics

$3.26

-0.16 (-4.68%)

16:51
04/09/18
04/09
16:51
04/09/18
16:51

vTv Therapeutics STEADFAST study misses both endpoints, study to be discontinued

vTv Therapeutics announced that results from part A of the company's Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer's disease did not meet either co-primary efficacy endpoint. Patients taking azeliragon compared with placebo did not improve in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale, or ADAS-cog, and the Clinical Dementia Rating Scale Sum of Boxes, or CDR-sb. The STEADFAST study is comprised of two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials. The azeliragon treated group in part A had a 4.4 point decline from baseline in ADAS-Cog and a 1.6 point decline from baseline in CDR-sb compared to a placebo decline of 3.3 and 1.6 respectively. These differences were not statistically significant. Azeliragon was generally well-tolerated with a 25% withdrawal rate over 18 months that was similar in both the placebo and treatment arms. vTv Therapeutics is discontinuing current clinical studies involving azeliragon, including the open-label extension study and Part B of the STEADFAST study. Given the progress to date of STEADFAST Part B, the company expects that a substantial portion of the patients in Part B of STEADFAST will have completed 12 months of treatment under the study protocol. vTv Therapeutics will continue to thoroughly evaluate subset data from Part A and then the dataset from Part B over the coming weeks.

VTVT vTv Therapeutics
$3.26

-0.16 (-4.68%)

03/29/18
GHSC
03/29/18
INITIATION
Target $14
GHSC
Buy
vTv Therapeutics initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated vTv Therapeutics with a Buy and $14 price target telling investors Azeliragon is a potential catalyst with the first of two Phase 3 trials in Alzheimer's expected read out in April. Davis believes vTv's current valuation is reflecting the Street's expectation of a low probability of success, which he views as a buying opportunity. If Phase 3 is positive, with a lowered discount rate of 10% from 40%, the analyst estimates shares would translate to a $45 share price, and if unsuccessful, shares could trade to the company's cash value of about 37c per share.
03/08/18
ROTH
03/08/18
INITIATION
Target $17
ROTH
Buy
vTv Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Robert LeBoyer started vTv Therapeutics with a Buy rating and $17 price target, noting that its lead product, Azeliragon, is in Phase 3 clinical trials to slow progression of Alzheimer's disease, and additional products based on its proprietary drug discovery platform are also in clinical development for type 1 and type 2 diabetes and preclinical studies.
02/08/18
02/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Q2 Holdings (QTWO) initiated with an Outperform at Wells Fargo. 2. Oasis Petroleum (OAS) initiated with an Outperform at Credit Suisse. 3. vTv Therapeutics (VTVT) initiated with an Outperform at Northland. 4. Delphi Technologies (DLPH) initiated with a Neutral at Buckingham. 5. Kennametal (KMT) re-established with an Outperform at Barrington. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/18
NORL
02/08/18
INITIATION
Target $28
NORL
Outperform
vTv Therapeutics initiated with an Outperform at Northland
Northland initiated vTv Therapeutics with an Outperform and $28 price target.

TODAY'S FREE FLY STORIES

GPS

Gap

$25.60

0.95 (3.85%)

10:46
11/21/18
11/21
10:46
11/21/18
10:46
OnTheFly
Gap rises amid potential store closures as namesake brand sales continue slide »

Shares of Gap (GPS) are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

10:45
11/21/18
11/21
10:45
11/21/18
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/21/18
11/21
10:45
11/21/18
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

KSS

Kohl's

$65.28

0.83 (1.29%)

10:40
11/21/18
11/21
10:40
11/21/18
10:40
Options
Bullish call spread in Kohls after recent weakness in shares »

Bullish call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:40
11/21/18
11/21
10:40
11/21/18
10:40
General news
The U.S. 1.4% October existing home sales rise »

The U.S. 1.4% October…

10:40
11/21/18
11/21
10:40
11/21/18
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DE

Deere

$145.63

7.14 (5.16%)

10:37
11/21/18
11/21
10:37
11/21/18
10:37
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere raises 2022…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

DE

Deere

$144.30

5.81 (4.20%)

10:32
11/21/18
11/21
10:32
11/21/18
10:32
Hot Stocks
Breaking Hot Stocks news story on Deere »

Deere sees grain demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

10:31
11/21/18
11/21
10:31
11/21/18
10:31
General news
Crude inventories for week of November 16 »

Crude oil inventories…

JNJ

Johnson & Johnson

$143.12

-3.32 (-2.27%)

10:30
11/21/18
11/21
10:30
11/21/18
10:30
Options
J&J puts active as shares see relative weakness »

J&J puts active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

10:30
11/21/18
11/21
10:30
11/21/18
10:30
General news
FX Action: The dollar »

FX Action: The dollar…

DE

Deere

$143.26

4.77 (3.44%)

10:29
11/21/18
11/21
10:29
11/21/18
10:29
Hot Stocks
Deere says U.S. farmers, dealers 'cautiously optimistic' »

Says record yields,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 27

    Nov

AVGO

Broadcom

$229.32

1.63 (0.72%)

, VLKAY

Volkswagen

$0.00

(0.00%)

10:28
11/21/18
11/21
10:28
11/21/18
10:28
Periodicals
Breaking Periodicals news story on Broadcom, Volkswagen »

Broadcom said to settle…

AVGO

Broadcom

$229.32

1.63 (0.72%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMZN

Amazon.com

$1,520.59

24.99 (1.67%)

10:27
11/21/18
11/21
10:27
11/21/18
10:27
Periodicals
Amazon contacting some users about error that exposed emails, The Verge says »

Amazon has been emailing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

10:25
11/21/18
11/21
10:25
11/21/18
10:25
General news
U.S. leading index rose 0.1% to 112.1 in October, another record high »

U.S. leading index rose…

TLC

Taiwan Liposome

$0.00

(0.00%)

10:21
11/21/18
11/21
10:21
11/21/18
10:21
Syndicate
Taiwan Liposome opens at $6.06, IPO priced at $5.80 per share »

Taiwan Liposome (TLC)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NVDA

Nvidia

$150.33

1.19 (0.80%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Technical Analysis
Technical Take: Nvidia goes negative on the day »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
U.S. October existing home sales bounced 1.4% to 5.220 M »

U.S. October existing…

JD

JD.com

$20.24

0.75 (3.85%)

10:20
11/21/18
11/21
10:20
11/21/18
10:20
Options
Third day of call buying in JD »

Third day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
Treasury Action: yields steadied above lows »

Treasury Action: yields…

10:20
11/21/18
11/21
10:20
11/21/18
10:20
General news
The Michigan sentiment drop »

The Michigan sentiment…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/21/18
11/21
10:17
11/21/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/21/18
11/21
10:16
11/21/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
11/21/18
11/21
10:15
11/21/18
10:15
General news
Breaking General news story  »

Week of 11/16 EIA…

WDC

Western Digital

$46.68

0.99 (2.17%)

10:10
11/21/18
11/21
10:10
11/21/18
10:10
Options
Western Digital weekly calls active as shares gain 3% »

Western Digital weekly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.